A new CCR5 antagonist in advanced clinical trials for treatment of HIV infection is cenicriviroc (TAK-652), which is a second-generation small-molecule CCR5 antagonist and dual chemokine receptors inhibitor for CCR2 and CCR554. Here, CCR5 is linked to HIV infectious disease.